Theme leaders: Daria Julkowska, E-Rare, France and Lauren Roberts, SWAN Europe, UK
Session 1: Transformations in diagnostics: How research is re-shaping the diagnosis landscape.
Session 2: Research: from an idea to the real world.
Session 3: Innovative funding partnerships: Challenges and opportunities.
Session 4: Patient involvement: Is it enough to be an ‘expert by experience’?
Session 5: Genome editing: Are we heading towards a world without rare diseases?
In the last few years, the research and diagnosis landscape has changed significantly in the field of rare diseases. Integration of new technologies in healthcare, and increased connection between research and care has opened up new possibilities for faster diagnosis and treatment. Acknowledging the patient as a key actor in their own health and putting them at the centre is strongly contributing to these tangible benefits. Encouraged by collaborative achievements of rare diseases stakeholders, the IRDiRC has published new, more ambitious goals and Europe is at the point of launching an integrative joint programming rare diseases initiative. But are we yet close to a fully collaborative and effective ecosystem that can provide all rare disease patients a diagnosis within a year?
The “STRUCTURING THE RESEARCH AND DIAGNOSTIC LANDSCAPE” theme will explore how we can exploit current achievements in genomics, how to prepare for new developments on the horizon and how to ensure no patients are left behind.
Starting by exploring how recent advances in research have transformed diagnostic pathways, we will also examine the potential challenges associated with new technology enabling self diagnosis and consider how we support those patients for who, despite these all innovations, their condition is likely to remain undiagnosed.
Assuming cooperation between patients, clinicians, researchers and sponsors to be the bedrock upon which successful research occurs, the next sessions will investigate what is required to aid this collaboration. Sessions two and three will explore recent, innovative schemes of co-design and funding, how to carry out research that profits all stakeholders and provide examples of how to attract investment. In session four we will challenge the idea of whether it is enough for a patient to simply be ‘an expert by experience’ and consider what skills and experience is required for them to truly be respected, equal partners.
In the closing session we expect lively debate as we invite ethicists, researchers and patients to scrutinize the impact of recent developments in gene editing – are we heading towards a world without rare diseases?
Theme leaders: François Houÿez, EURORDIS, France; Wim Goettsch, EUNetHTA, Netherlands and Jordi Linares Garcia, Head of Scientific and Regulatory Management, EMA
More information to come soon.
Theme leader: Julian Isla, Microsoft, Spain and Justina Januševičienė, Lithuanian University of Health Sciences, Lithuania
While other industries are fully immersed in the digital era, the health industry is struggling to undergo a real digital transformation. The foundations of health science date back centuries and the transition to the digital world is complex. The obstacles to create digital assets and relationships in the field of health range from unbalanced physician-patient relationships to clinical institutions focused on transactions and non-continuous care. Patients with rare diseases are suffering from this situation even more than other chronic patients: the complexity of their conditions, the low number of patients and the scarcity of effective treatments are big problems but also are great opportunities for a new medicine based on the P4 pillars (predictive, preventive, personalised and participatory). We will explore how technology can help patients with rare diseases, how the regulatory world is evolving, the initiatives in Europe to embrace this digital transformation and real examples from patient organisations already starting this journey. New technology will create fabulous opportunities but also new risks, as information will be more accessible to hackers and medical systems will be more exposed to cyberattacks. Information and awareness are elements crucial to understand in order to mitigate the risks while we are evolving into a new era of medicine.
Theme leaders: Lene Jensen, Rare Diseases Denmark and Ursula Holtgrewe, Zentrum für Soziale Innovation, Austria
Rare diseases pose serious health, social and everyday challenges, which are often highly debilitating, and significantly affect the autonomy and the fundamental human rights of people living with a rare disease and their carers. However, people living with rare diseases and their carers should be recognised and esteemed as persons, not as diagnoses. They should have the possibility of living a life with fulfilling personal relationships,of being able to contribute meaningfully to the lives of others and to society. Freedom to decide on their own lives, autonomy, security and dignity are important factors of what we call “quality of life”.
All rare disease stakeholders are working to improve the quality of life of all rare people. Nevertheless, health and social systems was well as the different spheres of access to care, treatment and support to inclusion and participation in society do not always successfully address their complex needs in ways that create actual improvements. How can we continue to build win-win collaborative strategies to advance this mission?
This theme revisits the concept of quality of life and explores the ways in which it can contribute to decision making and to shaping the provision of treatments and care. Discussions will also unveil the invisible burden of rare diseases and explore case studies of innovative services that bridge the existing gaps to effectively and sustainably achieving integrated care.
Lastly, the theme will venture into thinking of how care may look like in 30 years and how all stakeholders can prepare to develop the next best practices, building on the advances and challenges of tomorrow rather than those of today.
Theme leaders: Michael Schlander – Professor of Health Economics, University of Heidelberg, Germany and Ruediger Gatermann – Director, Healthcare Policy and External Affairs Europe, CSL Behring, Germany
The theme will aim to look at economical aspects in rare diseases from different stakeholder perspectives, evaluate existing collaborative approaches and discuss options to further develop an environment conducive to innovation and to faster access to patients care and cure.
The sessions in this theme will explore our ambitions to refine a shared understanding on how to improve access to rare disease therapies and how to ensure a sustainable orphan drug business model for all stakeholders involved.
We will share findings on economic and financial impact of rare diseases on healthcare systems and societies, including testimonials/case studies from patients.
The theme will look both into the impact of the current policies on access to rare disease therapies as well as into innovative concepts and collaborative approaches which are being experimented throughout Europe both in view of value recognition, rewarding and funding.
A look into the future will complete the theme to explore consensual ideas on what is needed to further develop the rare diseases ecosystem and how to ensure sustainable access to rare disease care in 2030.
Theme leaders: Durhane Wong-Rieger, Canadian Organisation for Rare Disorders, Chair of Rare Diseases International, Founder of the Asia Pacific RD Alliance (APARDO), Canada and Hugh Dawkins, Office of Population Health Genomics, West Australia and Vice Chair of IRDiRC, Australia.
It’s time to commit to global equity for rare diseases. When rare diseases are neglected anywhere, people living with a rare disease are harmed everywhere.
People with rare diseases are connected globally by their genes and their challenges; they should also be connected by their hope and opportunities. Our vision is a world where all people living with rare diseases receive equitable treatment and support and all advances in rare diseases benefit all those affected, regardless of where they live.
This theme is set up as five inter-related workshop sessions that explore how to achieve global equity for rare diseases from top-down and from bottom-up levels, from policy and research to products and practical solutions.
Each session will be facilitated by an animateur with several “thought leaders” who will set the stage for total audience participation.
Programme Committee Co-chairs
Programme Commitee members